AF
PTCT icon

Amalgamated Financial’s PTC Therapeutics PTCT Stock Holding History

Amalgamated Financial’s Portfolio PTCT Stock Details PTCT Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2022
Q1 		$424K Buy
+11,370
New +$438K ﹤0.01% 1594

Other funds holding PTCT

Fidelity Investments
Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return
Wellington Management Group
Wellington Management Group Boston, Massachusetts $535B AUM 26.23% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
RI
RTW Investments New York $10B AUM 135.35% 1-Year Est. Return
Franklin Resources
Franklin Resources San Mateo, California $408B AUM 30.18% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return
AC
Armistice Capital New York $5.62B AUM 36.06% 1-Year Est. Return
Janus Henderson Group
Janus Henderson Group London, United Kingdom $209B AUM 37.72% 1-Year Est. Return
CCM
Camber Capital Management Boston, Massachusetts $1.07B AUM 8.19% 1-Year Est. Return

Amalgamated Financial's PTCT Position: Q1 2022 in Review

Amalgamated Financial opened a new position in PTC Therapeutics (PTCT) in Q1 2022: 11,370 shares worth $424K. The stake represents ﹤0.01% of the portfolio and ranks #1594 among its holdings.

184 funds tracked by Wall St. Rank hold PTCT as of Q1 2022.

  • Amalgamated Financial held 11,370 shares of PTC Therapeutics worth $424K as of Q1 2022.
  • PTC Therapeutics was a new Amalgamated Financial position in Q1 2022.
  • PTC Therapeutics made up ﹤0.01% of Amalgamated Financial's portfolio in Q1 2022, its #1594 holding.
  • 184 funds tracked by Wall St. Rank held PTC Therapeutics as of Q1 2022.

Based on Amalgamated Financial's 13F filing for Q1 2022, filed 16 May 2022.